A highly potent antibody effective against SARS-CoV-2 variants of concern.
Details
Download: cell report.pdf (4653.47 [Ko])
State: Public
Version: Final published version
License: All rights reserved
State: Public
Version: Final published version
License: All rights reserved
Serval ID
serval:BIB_6CC56B59453A
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Journal
Cell reports
ISSN
2211-1247 (Electronic)
Publication state
Published
Issued date
12/10/2021
Peer-reviewed
Oui
Volume
37
Number
2
Pages
109814
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Publication Status: ppublish
Abstract
Control of the ongoing SARS-CoV-2 pandemic is endangered by the emergence of viral variants with increased transmission efficiency, resistance to marketed therapeutic antibodies, and reduced sensitivity to vaccine-induced immunity. Here, we screen B cells from COVID-19 donors and identify P5C3, a highly potent and broadly neutralizing monoclonal antibody with picomolar neutralizing activity against all SARS-CoV-2 variants of concern (VOCs) identified to date. Structural characterization of P5C3 Fab in complex with the spike demonstrates a neutralizing activity defined by a large buried surface area, highly overlapping with the receptor-binding domain (RBD) surface necessary for ACE2 interaction. We further demonstrate that P5C3 shows complete prophylactic protection in the SARS-CoV-2-infected hamster challenge model. These results indicate that P5C3 opens exciting perspectives either as a prophylactic agent in immunocompromised individuals with poor response to vaccination or as combination therapy in SARS-CoV-2-infected individuals.
Keywords
General Biochemistry, Genetics and Molecular Biology, SARS-CoV-2, neutralizing antibodies, variants of concern
Pubmed
Web of science
Open Access
Yes
Funding(s)
Swiss National Science Foundation
CHUV
Create date
04/10/2021 9:57
Last modification date
27/08/2024 9:51